Category - Developments

Developments

Firefly builds world’s first 200,000+ EEG/ERP brain scan depository

Firefly Neuroscience (NASDAQ: AIFF) has achieved a major operational and commercial milestone with more than 200,000 EEG/ERP (human brain function) scans. Through its acquisition of Evoke Neuroscience in May 2025...

April 13, 2026

Developments

MetaVia doses first patient in study of DA-1726 in obesity

MetaVia (NASDAQ: MTVA) has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. According to MetaVia, Part 3...

April 10, 2026

Developments

Annovis’ $10 million financing secures path to NDA for buntanetap in AD

Annovis Bio (NYSE: ANVS) has announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds extending its cash runway through Phase 3 Alzheimer’s disease (AD) six-month NDA...

April 10, 2026

Developments

Emergent partners with B.C. to supply NARCAN for take-home program

Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the British Columbia (B.C.) Provincial Health Services Authority (PHSA) to supply NARCAN Nasal Spray for the province’s Take-Home Naloxone Program...

April 10, 2026

Developments

AMA approves code for Plus’ CNSide CSF TCE test

Plus Therapeutics (NASDAQ: PSTV) has announced that the American Medical Association (AMA) has approved a new proprietary laboratory analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide Cerebrospinal...

April 7, 2026

Developments

UACC initiates study of Fennec’s PEDMARK for AYA and adult cancers

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection...

April 7, 2026

Developments

NervGen completes EOP2 meeting and aligns with FDA on Phase 3 study

NervGen Pharma (NASDAQ: NGEN) has announced the completion of a successful end-of-Phase 2 (EOP2) meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for...

April 7, 2026

Developments

Vyome to present compelling data on treatment for MFW at AACR

Vyome Holdings (NASDAQ: HIND) has announced it will present its full Phase 2 investigator-initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor...

April 6, 2026

Developments

Medicus submits study design to FDA for Teverelix in AURr

Medicus Pharma (NASDAQ: MDCX) has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention (AURr) in men...

April 6, 2026

Developments

FDA clears Stereotaxis’ Synchrony system

Stereotaxis (NYSE: STXS) has received FDA 510(k) clearance for its Synchrony system, designed to digitize and modernize the interventional cath lab. According to Stereotaxis, Synchrony is made available with SynX, a...

April 6, 2026

Category - Developments

Subscribe